The US FDA has just announced that on September 8, 2011, the FDA Cardiovascular and Renal Drugs Advisory Committee will meet to review whether to recommend approval of rivaroxaban (brand name Xarelto), an alternative to warfarin, for stroke prevention in atrial fibrillation.
In this recent video interview, Dr. Elaine Hylek, a leading anticoagulant authority, discussed the new novel anticoagulants that overcome many of the problems of the current blood thinner, warfarin (Coumadin). She reviewed the ROCKET AF clinical trial results for rivaroxaban and the RE-LY clinical trial results for the currently-approved dabigatran (brand name Pradaxa). She also spoke briefly about the ARISTOTLE trial for apixaban and the trial for edoxaban, both of which may also become alternatives to warfarin.
Watch the video or read the transcript at: